



#17/12

Attorney Docket No.: 5835.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Bisgård-Frantzen et al Confirmation No: 9183
Serial No.: 09/710,339 Group Art Unit: 1651
Filed: November 9, 2000 Examiner: Momshipouri, M.
For: Fungamyl-like Alpha-Amylase Variants

RECEIVED
JAN 07 2003
TECH CENTER 1600/2900

AMENDMENT FEE TRANSMITTAL

Commissioner for Patents
Washington, DC 20231

Sir:

Transmitted herewith is an Amendment for the above-identified application in response to the Office Action mailed July 3, 2002.

It is respectfully requested that the time for response to the Office Action be extended for a period of 3 months from October 3, 2002 to January 3, 2003. The required fee for the extension is estimated to be \$930.

No additional claims fee is required.

Please charge the required extension fee, estimated to be \$930, to Novozymes North America, Inc., Deposit Account No. 50-1701. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: January 3, 2003



Jason I. Garbell, Reg. No. 44,116
Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212) 840-0097

01/06/2003 MBLAND 00000017 501701 09710339

01 FC:1253 930.00 CH



#18 c/p

02-03-03

Attorney Docket No.: 5835.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Bisgård-Frantzen et al Confirmation No: 9183

Serial No.: 09/710,339

Group Art Unit: 1651

Filed: November 9, 2000

Examiner: Momshipouri, M.

For: Fungamyl-like Alpha-Amylase Variants

AMENDMENT UNDER 37 C.F.R. 1.111

Commissioner for Patents
Washington, DC 20231

Sir:

In response to the Office Action mailed July 3, 2002, please amend the above-identified application as follows (a marked up version pursuant to 37 C.F.R. 1.21 is attached hereto):

IN THE CLAIMS:

Please cancel claims 34-38, 44-47 and 49, without prejudice or disclaimer.

Please substitute the following amended claims for the pending claims having the same claim numbers:

31. (Amended.) A variant of a parent Fungamyl-like alpha-amylase, comprising an alteration at one or more regions selected from the group consisting of:

Region 98-110,

Region 150-160,

Region 161-167,

Region 280-288,

Region 448-455, and

Region 468-475;

wherein (a) the alteration(s) are independently

(i) an insertion of an amino acid downstream of the amino acid which occupies the position,

(ii) a deletion of the amino acid which occupies the position, or

(iii) a substitution of the amino acid which occupies the position with a different amino acid,

(b) the variant has alpha-amylase activity and (c) each region or position corresponds to a region or position of the amino acid sequence of the parent Fungamyl-like alpha-amylase having the

C'

C'
cont. amino acid sequence of SEQ ID NO: 2.
